Resultados: 67

Systematic review and meta-analysis of second-generation sham-controlled randomized trials of renal denervation therapy for patients with hypertension

INTRODUCTION: Renal denervation has been associated with substantial and sustained blood pressure reduction and is considered to serve as an alternative treatment for patients with resistant hypertension. However, the first published SHAM-controlled trial assessing RDN safety and efficacy showed no diffe...

Percutaneous revascularization in late-presenting STEMI with absence of viability: effects on left ventricular remodeling and scar

Eur. heart j; 45 (Suppl. 1), 2024
INTRODUCTION: In patients with ST-elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) should be conducted within 12 hours of symptom onset. The potential benefits attributable to late reperfusion in STEMI fall under the "open artery hypothesis" where the stunned peri-infarct...

Clinical and genetic profiles of patients with hereditary and wild type transthyretin amyloidosis: the transthyretin cardiac amyloidosis registry in the state of Sao Paulo, Brazil REACT-SP

Eur. heart j; 45 (Suppl. 1), 2024
INTRODUCTION: Transthyretin amyloidosis (ATTR) is a multisystem disease caused by the deposition of fibrillar protein in organs and tissues. ATTR genotypes and phenotypes are highly heterogeneous. PURPOSE: We designed the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo (REACT-SP), a...

Bevacizumab-induced hypertension in patients with glioblastoma: a systematic review and meta-analysis

Eur. heart j; 45 (Suppl. 1), 2024
BACKGROUND: Bevacizumab is a monoclonal antibody medication used as standard treatment for different types of cancers, one of them is glioblastoma, which is the most common primary brain tumor. PURPOSE: We aimed to assess bevacizumab and its effects on inducing hypertension in patients with glioblastoma....

Comparison of intensive treatment versus standard treatment in lowering blood pressure and its association with cognitive decline and dementia: a systematic review and meta-analysis

Eur. heart j; 45 (Suppl. 1), 2024
BACKGROUND: The ideal blood pressure target level for preventing cognitive decline or dementia in patients with systemic arterial hypertension (SAH) remains unclear. PURPOSE: This study aims to investigate whether intensive blood pressure reduction compared to standard treatment is associated with a redu...

Assessing the efficacy of renal denervation in patients with resistant arterial hypertension: a systematic review and meta-analysis

Eur. heart j; 45 (Suppl. 1), 2024
BACKGROUND/INTRODUCTION: Renal denervation (RDN) is an innovative procedure designed to regulate the renal sympathetic nervous system for the control of arterial hypertension (HTN). RDN emerges as an alternative for patients with resistant arterial hypertension. Despite this, the clinical efficacy of RDN...

Safety and efficacy of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis

Eur. heart j; 45 (Suppl. 1), 2024
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD), affects approximately 18.6 million individuals worldwide, poses an important healthcare challenge. Despite the established efficacy of both high-intensity statin monotherapy (HIS) and moderate-intensity statin plus ezetimibe (MIS+EZT) in ASCVD m...

Ablação de taquicardia ventricular em pacientes com cardiomiopatia chagásica dilatada: mortalidade em 30 dias pós procedimento
Ablation of ventricular tachycardia in patients with dilated chagasic cardiomyopathy: mortality within 30 days after the procedure

Int. j. cardiovasc. sci. (Impr.); 37 (suppl.9), 2024
INTRODUÇÃO: A ablação por cateter de Taquicardia Ventricular (TV) em pacientes com Cardiomiopatia Chagásica Dilatada (CCD) pode ser desafiadora devido à complexidade do substrato. Afinalidade do procedimento é a redução do número de TVs e de terapias dos cardiodesfibriladores implantáveis, res...

Epicardial substrate ablation in high-risk brugada syndrome patients: systematic review and single-arm meta-analysis

Int. j. cardiovasc. sci. (Impr.); 37 (suppl.9), 2024
INTRODUCTION: Brugada syndrome (BrS) is a genetic heart disease that predisposes individuals to malignant ventricular arrhythmias and sudden cardiac death (SCD). Although implantable cardioverter-defibrillators (ICDs) and quinidine are primary treatments, recurrent BrS-triggered cardiac ventricular arrhy...

Sirolimus-eluting stent with abluminal-only biodegradable polymeric coating in the treatment of native coronary artery lesions: results of the prospective multicenter inspiron real life II and latitude Trials

J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND Inspiron is a third-generation drug-eluting stent with abluminal-only biodegradable polymeric coating designed for fast and homogeneous reendothelialization, possibly improving clinical outcomes. This study aimed to evaluate the safety and clinical performance of the Inspiron sirolimus-eluting...